Northwest Biotherapeutics Q3 2026 Results: Net Loss of $28.8M, Loss Widens
Northwest Biotherapeutics reported a net loss of $41.1 million for the nine months ended September 30, 2026, an improvement from the $61.6 million loss in the prior year period. Total revenues increased to $2.2 million from $0.7 million, while operating expenses decreased significantly from $47.1 million to $34.6 million.
- Key figure
- Net loss $28.8M